^
    5d
    Malignant vascular neoplasms of the distal female genital tract: a series of 19 cases emphasizing unusual features and diagnostic challenges. (PubMed, Histopathology)
    While many morphologic features of vascular lesions at this site are shared with those of extra-genital soft tissues, pathologists must be aware that these tumours may occur in the vulvovaginal area and display unconventional clinical profiles. As such, a broad differential for epithelioid and spindle cell neoplasms at this site is prudent.
    Journal
    |
    CAMTA1 (Calmodulin Binding Transcription Activator 1)
    7d
    The Changing Face of HIV-Associated Malignancies: Is this the Same in Turkey As Well? (PubMed, Curr HIV Res)
    These findings highlight that AIDS-defining cancers continue to be a significant clinical concern in Turkey. Cancer screening should be integrated both at the time of HIV diagnosis and during routine follow-up of PLWH.
    Journal
    |
    CD4 (CD4 Molecule)
    10d
    Transcriptome and m6A epitranscriptome profiling reveal CCL20 as a key mediator of inflammation in Staphylococcus aureus-induced bovine mastitis. (PubMed, BMC Microbiol)
    These findings suggest that m6A-mediated regulation of CCL20 in S. aureus-induced BMECs operates via the PI3K/Akt/NF-κB pathway. These findings underscore the significance of m6A-mediated CCL20 regulation in mastitis pathogenesis and suggest potential therapeutic strategies for managing this economically significant disease in dairy farming.
    Journal
    |
    IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CCL20 (C-C Motif Chemokine Ligand 20) • IL10 (Interleukin 10) • IL17A (Interleukin 17A) • YTHDF2 (YTH N6-Methyladenosine RNA Binding Protein 2)
    10d
    A Study of Propranolol to Treat Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=25, Not yet recruiting, AIDS Malignancy Consortium | Trial completion date: Jun 2027 --> Apr 2029 | Trial primary completion date: Jun 2027 --> Apr 2029
    Trial completion date • Trial primary completion date
    10d
    Paclitaxel and Pegylated Liposomal Doxorubicin for Treatment of HIV-related Kaposi Sarcoma (clinicaltrials.gov)
    P3, N=130, Not yet recruiting, AIDS Malignancy Consortium | Trial completion date: Nov 2027 --> Sep 2030 | Trial primary completion date: Dec 2026 --> Sep 2029
    Trial completion date • Trial primary completion date • Head-to-Head
    |
    paclitaxel • pegylated liposomal doxorubicin
    11d
    Understanding the Burden of Coinfection: COVID-19 in Hospitalized Patients with Diagnosed and Undiagnosed Advanced HIV. (PubMed, Curr HIV Res)
    These findings can provide physicians with a risk-based prioritization algorithm for patients with COVID-19 and advanced HIV coinfection. Identifying patients at highest risk for unfavorable outcomes ensures timely ICU admission, faster patient examination, and initiation of dedicated treatment.
    Journal
    |
    CD4 (CD4 Molecule)
    11d
    PULSAR: Pembrolizumab Plus Lenvatinib in Previously Treated Classic Kaposi Sarcoma (clinicaltrials.gov)
    P2, N=0, Withdrawn, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico | N=25 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    13d
    Assessment of Bone Mineral Density in People Living With HIV and KSHV Associated Malignancies: A Retrospective Longitudinal Analysis (clinicaltrials.gov)
    P=N/A, N=40, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Dec 2025 --> Dec 2027 | Trial primary completion date: Dec 2025 --> Dec 2027
    Trial completion date • Trial primary completion date
    14d
    Pomalidomide in Combination With Liposomal Doxorubicin in People With Advanced or Refractory Kaposi Sarcoma (clinicaltrials.gov)
    P1, N=62, Active, not recruiting, National Cancer Institute (NCI) | Trial completion date: Jan 2028 --> Jan 2029 | Trial primary completion date: Jan 2026 --> Jan 2028
    Trial completion date • Trial primary completion date
    |
    pomalidomide
    15d
    Anwei decoction alleviates chronic atrophic gastritis by modulating the gut microbiota-metabolite axis and NLRP3 inflammasome activity. (PubMed, World J Gastroenterol)
    AWD alleviates the pathological progression of CAG through multi-target synergistic mechanisms. On one hand, AWD directly suppresses gastric mucosal inflammation by inhibiting NLRP3 inflammasome activation. On the other hand, AWD remodels intestinal microbiota-metabolite homeostasis, enhances intestinal barrier function, and regulates mucosal immune responses.
    Journal
    |
    TNFA (Tumor Necrosis Factor-Alpha) • IL18 (Interleukin 18) • IL1B (Interleukin 1, beta) • NLRP3 (NLR Family Pyrin Domain Containing 3)
    21d
    CD13 activation assembles phosphoinositide (PI) signaling complexes to regulate the actin cytoskeleton. (PubMed, Sci Rep)
    This activates phosphatidylinositol-4-phosphate-5-kinase (PI5K) to increase local phosphatidylinositol 4,5-bisphosphate (PI(4,5)P2) levels, promoting actin-polymerization and membrane protrusion. Therefore, CD13 is a novel molecular PIP regulator, modulating signal transduction and downstream cellular processes, including actin cytoskeleton dynamics and membrane organization to facilitate intercellular communication.
    Journal
    |
    CDC42 (Cell Division Cycle 42) • ANPEP (Alanyl Aminopeptidase, Membrane) • IQGAP1 (IQ Motif Containing GTPase Activating Protein 1)